# Siegfried

# Siegfried at a Glance

As a worldwide leading contract and development manufacturing organization, we produce pharmaceutical ingredients and finished products as an integrated supplier.

#### What is a CDMO?

A CDMO (Contract Development and Manufacturing Organization) is a company that offers both process development (contract development) and manufacturing services. Comprehensive services range from early-stage Research & Development services such as synthesis, scale up, formulation development, stability studies and method development all the way through to manufacturing services, ranging from preclinical R&D material for clinical trial purposes and commercial production (Phases I–IV).

## **Drug Substances**

APIs, Intermediates
Controlled substances



# **Drug Products**

Solid dosage forms (including capsules for inhalation)

Semi-solid dosage forms (ophthalmic ointments)

Liquid dosage forms (sterile and non-sterile)

### Active pharmaceutical ingredients

(APIs) are used in the production of a medication. APIs are the key ingredient of an end product that is ready for administration with a direct effect concerning treatment.

Intermediates are created in the course of a multi-stage chemical reaction. They are not final products but the result of the previous step and the initial product for the following reaction step.

Controlled substances are chemicals, whose production, ownership and use are strictly regulated by international conventions and national legislation. The aim is to make allowance for scientific or medical applications while at the same time to prevent misuse and illegal trade.

Oral solid dosage forms In galenics – the science of the preparation of medicinal products – active pharmaceutical ingredients (APIs) are applied in a suitable dosage and delivered precisely to where they are required in the body. The API is mixed with certain auxiliary materials and then processed to a liquid, solid or semisolid dosage form. In the field of oral solid dosage forms, tablets and capsules prevail.

### Liquid sterile and aseptic dosage forms

Sterile filling is the aseptic production of drugs and one of the most demanding processes in galenic production. Aseptic production process imposes high demands on rooms, air quality, staff, raw materials and surfaces.

### Competencies

|                        |      |                      |                               | Å   |
|------------------------|------|----------------------|-------------------------------|---|
| Locations              |      | With Siegfried since | Number of permanent employees | Competencies  |
| Zofingen <sup>HQ</sup> | DS   | 1873                 | 650                           | Active pharmaceutical ingredients (API), Intermediates, Controlled Substances |
| Pennsville             | DS   | 1928                 | 183                           | Active pharmaceutical ingredients (API), Intermediates, Controlled Substances |
| Hal Far                | DP   | 2007                 | 141                           | Solid oral dosage forms   |
| Irvine                 | DP   | 2012                 | 133                           | sterile and aseptic filling   |
| Nantong                | DS   | 2013                 | 274                           | Active pharmaceutical ingredients (API), Intermediates                        |
| Hameln                 | DP   | 2014                 | 513                           | sterile and aseptic filling   |
| Minden                 | DS   | 2015                 | 409                           | Active pharmaceutical ingredients (API), Intermediates, Controlled Substances |
| Evionnaz               | DS   | 2015                 | 353                           | Active pharmaceutical ingredients (API), Intermediates                        |
| St.Vulbas              | DS   | 2015                 | 140                           | Active pharmaceutical ingredients (API), Intermediates                        |
| Barberà del Vallès     | DP   | 2021                 | 522                           | Solid oral dosage forms   |
| El Masnou              | DP   | 2021                 | 362                           | sterile and aseptic filling   |
| DS : Drug Substances   | DP : | Drug Products        |                               |   |

### Addresses

Switzerland: Siegfried AG (Headquarters) Untere Bruehlstrasse 4 4800 Zofingen

Sieafried Evionnaz SA Route du Simplon 1,36 1902 Evionnaz

Germany:

Siegfried Hameln Langes Feld 13 31789 Hameln

Siegfried PharmaChem. Minden GmbH Karlstrasse 15 32423 Minden

Malta:

Siegfried Malta Ltd HHF070 Hal Far Industrial Estate Hal Far BBG 3000

France:

Siegfried St. Vulbas SAS Parc Industriel de la Plaine de l'Ain 530 Allée de la Luve 01150 St. Vulbas

Spain:

Siegfried Barbera S.L. Ronda de Santa Maria 158 08210 Barberà del Vallès / Barcelona

Sieafried El Masnou Alcon Cusí, S.A. Camil Fabra, 58 08320 El Masnou

USA:

Siegfried USA, LLC 33 Industrial Park Road Pennsville, NJ 08070

Siegfried Irvine 9342 Jeronimo Road Irvine, CA 92618

China:

Siegfried (Nantong) Pharmaceuticals Co. Ltd. No. 5. Tongshun Road, NETDA Nantong City, Jiangsu Province P.R.C (post code: 226017)

### Locations



# Key Figures 2022

| Net sales (million CHF)   | 1229.5 |
|---|--------|
| Gross profit (million CHF)  | 318.9  |
| Gross profit margin (%)   | 25.9%  |
| Core EBITDA (million CHF)   | 272.5  |
| Core EBITDA margin (%)  | 22.2%  |
| Core EBIT (operating result) (million CHF)                                      | 190.8  |
| Core EBIT margin (%)  | 15.5%  |
| Core net profit (million CHF)   | 127.8  |
| Core net profit-margin in percentage  | 10.4%  |
| Non-diluted core earnings per share (CHF)                                       | 30.28  |
| Cash flow from operating activities (million CHF)                               | 142.3  |
| Investment in property, plant and equipment and intangible assets (million CHF) | 115.2  |
|   |        |

# 1229.5 mio.

Net sales reached 1 229.5 million Swiss francs (+11.5% in CHF / +15.6% in LC).

+31.5%

Core EBITDA amounts to 272.5 million Swiss francs (+31.5%).


127.8 mio.

Core net profit amounts to 127.8 million Swiss francs.

# **Employees**

Number of employees worldwide:

3680



A: Zofingen: 650 B: Pennsville: 183 C: Malta: 141 D: Irvine: 133 E: Nantong: 274 F: Hameln: 513 G: Minden: 409 H: Evionnaz: 353

I: St. Vulbas: 140

J: Barberà del Vallès: 522 K: El Masnou: 362

## Our Mission Our Vision Our Values

#### Our Mission

"With mastery of science and technology, we take the precious innovations of our pharmaceutical customers to industrial scale and manufacture safe drugs for patients worldwide"

#### Our Vision

"Siegfried is the most trusted partner of the pharmaceutical industry and the global leader in the CDMO space – because we are the strongest team running the most competitive network"

#### **Our Values**

"Our values and leadership principles are the basis to build the strongest team in the industry"

### **Our Values**



**Excellence** "We excel in everything we do"



**Passion** "We deeply care about what we do and how we do it"



**Integrity** "We act responsibly, reliably, respectfully and live up to our own standards"



Quality

"We do it right first time"



**Sustainability** "We do not only think about tomorrow, but far beyond"

## Siegfried's History

#### 1873

Foundation of Siegfried in Zofingen (CH)

#### 1928

Foundation of Ganes Chemical Works, Inc. in New Jersey (USA)

#### 1973

Listing on the Swiss
Stock Exchange (SWX)

#### 2005

Acquisition of Penick Corporation in New Jersey (USA)

#### 2007

Launch of a pharmaceutical production facility in Hal Far (MT)

#### 2012

Acquisition of Alliance Medical Products (AMP) in Irvine (USA)

#### 2014

Start of operation at facility in Nantong (CN)

Acquisition of Hameln Pharma in Hameln (DE)

#### 2015

Acquisition of segments of BASF's pharmaceutical supply business in Minden (DE), Evionnaz (CH) and St. Vulbas (FR)

#### 2021

Acquisition of two pharmaceutical production sites from Novartis in Barberà del Vallès and El Masnou (ES) The Siegfried Group is a global life sciences company with a network of 11 sites in Europe, the USA and Asia.

Siegfried offers contract developing and manufacturing of active pharmaceutical ingredients, intermediates and finished dosage forms.

Our integrated approach ensures that we can provide a range of services, from process development and optimization to registration, production, packaging and logistics.